Radius Health, Inc.

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Pacts With Exscientia, BenevolentAI Wil

Novartis AG outlined the details of its spin-off plans for its generics and biosimilars business Sandoz on 18 August, revealing the financial terms for the big pharma’s shareholders and the date of t

The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing approval for 15 new products, including talquetamab, Janssen ’s investigational bispecific antibody for